# US 2016/0243200 A1 · Medicament for treating olfaction disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243200 A1
- Document ID: US20160243200A1
- Status: Published application
- Kind: A1
- Application number: 15/046,858
- Filed: 2016-02-18
- Published: 2016-08-25
- Earliest claimed: 2015-02-19
- Inventors: Akihito KUBOKI; Shu KIKUTA
- Web page: https://patentgrep.com/patent/US20160243200A1

## CPC

- A61K 38/28: Insulins
- A61K 9/0043: {Nose}
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/16: Otologicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time. The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment.

## Claims

### Claim 1

An olfactory disturbance therapeutic agent comprising
at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues.

### Claim 2 (depends on 1)

The olfactory disturbance therapeutic agent according to claim 1, wherein
the agent is offered in a form of nasal preparation.

### Claim 3 (depends on 1, 2)

The olfactory disturbance therapeutic agent according to claim 1 or 2, wherein
the agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance.